[1] Karayiannis P. Hepatitis B virus: virology, molecular biology, life cycle and intrahepatic spread. Hepatol Int, 2017, 11(6):500-508. [2] Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev, 2017, 49(2):197-211. [3] 陈丽丽, 符茂雄, 蒙绪标,等. 空腹C肽评估NAFLD合并T2DM患者肝纤维化进展价值分析. 实用肝脏病杂志, 2020, 23(1):38-41. [4] Hu D, Wang H, Wang H, et al. Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model. Hepatol Int, 2018, 12(5):438-446. [5] 伺佳, 曾艳丽, 李威, 等. 非酒精性脂肪性肝病与其合并慢性乙型肝炎病毒感染的临床探讨. 中华肝脏病杂志, 2017, 25(8):618-622. [6] Farzanegi P, Dana A, Ebrahimpoor Z, et al. Mechanisms of beneficial effects of exercise training on non-alcoholic fatty liver disease (NAFLD): roles of oxidative stress and inflammation. Eur J Sport Sci, 2019, 19(7):994-1003. [7] Wang X, Hausding M, Weng SY, et al. Gliptins suppress inflammatory macrophage activation to mitigate inflammation, fibrosis, oxidative stress, and vascular dysfunction in models of nonalcoholic steatohepatitis and liver fibrosis. Antioxid Redox Signal, 2018, 28(2):87-109. [8] Polyzos SA, Mantzoros CS. Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review. Metabolism, 2016, 65(9):1297-1306. [9] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中华内科杂志, 2011, 50(2):168-179. [10] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志, 2010, 49(3):275-278. [11] 卞华, 张林杉, 颜红梅, 等. 利用非酒精性脂肪性肝病纤维化评分评估住院2型糖尿病患者的肝脏纤维化状况. 中华内分泌代谢杂志, 2014, 30(11):960-965. [12] 何京, 陈友鹏. 母婴乙型肝炎垂直传播影响因素与孕期抗病毒治疗进展. 中华传染病杂志, 2017, 35(5):311-314. [13] Joo EJ, Chang Y, Yeom JS, et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology, 2017, 65(3):828-835. [14] Suliman I, Abdelgelil N, Kassamali F, et al. The effects of hepatic steatosis on the natural history of HBV infection. Clin Liver Dis, 2019, 23(3):433-450. [15] Fang YL, Chen H, Wang CL, et al. Pathogenesis of non-alcoholic fatty liver disease in children and adolescence: from "two hit theory" to "multiple hit model". World J Gastroenterol, 2018, 24(27):2974-2983. [16] Han R, Ma J, Li H. Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota. Front Med, 2018, 12(6):645-657. [17] 张志侨, 王功遂, 康凯夫, 等. 基于216对配对病例研究慢性乙型肝炎患者肝脂肪变性的临床和病理特征. 中华传染病杂志, 2016, 34 (3):146-150. [18] Fujita M, Kuraji R, Ito H, et al. Histological effects and pharmacokinetics of lipopolysaccharide derived from porphyromonas gingivalis on rat maxilla and liver concerning with progression into non-alcoholic steatohepatitis. J Periodontol, 2018, 89(9):1101-1111. [19] Yu Y, Sun X, Gu J, et al. Deficiency of DJ-1 ameliorates liver fibrosis through inhibition of hepatic ROS production and inflammation. Int J Biol Sci, 2016, 12(10):1225-1235. [20] Dong Z, Su L, Esmaili S, et al. Adiponectin attenuates liver fibrosis by inducing nitric oxide production of hepatic stellate cells. J Mol Med, 2015, 93(12):1327-1339. [21] Kawaratani H, Moriya K, Namisaki T, et al. Therapeutic strategies for alcoholic liver disease: focusing on inflammation and fibrosis. Int J Mol Med, 2017, 40(2):263-270. [22] 魏雅楠, 邓利华, 王晶桐. 老年非酒精性脂肪性肝病患者纤维化评分与颈动脉不稳定斑块的相关性研究. 中华老年医学杂志, 2019, 38(11):1251-1253. [23] Cardoso A C, Beaugrand M, Ledinghen V D, et al. Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. Ann Hepatol, 2015, 14(6):826-836. [24] 徐亮, 钟燕, 苏淑婷, 等. 反应性氧化物、脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究. 中华肝脏病杂志, 2020, 28(3):247-253. [25] John BV, Aiken T, Garber A, et al. Recipient but not donor adiponectin polymorphisms are associated with early posttransplant hepatic steatosis in patients transplanted for non-nonalcoholic fatty liver disease indications. Exp Clin Transplant, 2018, 16(4):439-445. |